Nonnucleoside reverse transcriptase inhibitor resistance

Journal of Acquired Immune Deficiency Syndromes

Volumn 26, Issue SUPPL. 1, 2001, Pages

  Deeks, S G ^a  

^a SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

Cross resistance; Fitness; NNRTI resistance; Point mutations; Viral transmission

Indexed keywords

ANTIRETROVIRUS AGENT; CAPRAVIRINE; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; UNCLASSIFIED DRUG; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS RESISTANCE; DOUBLE BLIND PROCEDURE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POINT MUTATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS INFECTION; VIRUS LOAD; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS TRANSMISSION;

EID: 0035281213     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200103011-00004     Document Type: Review

References (36)

1. Nevirapine resistance mutations of human immunodeficiency virus type I selected during therapy
2. Viral dynamics in human immunodeficiency virus type I infection
3. Nevirapine-resistant human immunodeficiency virus: Kinetics of replication and estimated prevalence in untreated patients
4. Crystal structure of 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor
5. Novel mechanism of drug resistance due to Lys103Asn mutation suggested by crystal structures of unliganded and inhibitor-bound Lys103Asn HIV-1 RT
6. The P236L delavirdine-resistant human immunodeficiency virus type I mutant is replication defective and demonstrates alterations in both RNA 5′-end- and DNA 3′-end-directed RNase H activities
7. Relative fitness of efavirenz (EFV, DMP 266)-resistant mutants of HIV-1
8. Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission
9. Virologic failure during combination therapy with CRIXIVAN and RT inhibitors is often associated with expression of resistance-associated mutations in RT only
10. Patterns of resistance mutations selected by treatment of HIV-1 infection with zidovudine, didanosine and nevirapine
11. RT gene mutations associated with resistance to efavirenz
12. 3′-Azido-3′-deoxythymide resistance suppressed by a mutation conferring human deficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors
13. Resistance of HIV-1 clinical isolates to efavirenz and other NNRTIs
14. A mutation in reverse transcriptase of bis(heteroaryl) piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors
15. Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260)
16. HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine
17. Sequencing of non-nucleoside reverse transcriptase inhibitors based on specific mutational patterns fails to lower plasma HIV-RNA levels in persons extensively pre-treated with antiretrovirals who are failing virologically on nevirapine-containing antiretroviral regimens
18. Efavirenz- and adefovir dipvoxil-based salvage therapy in highly treatment-experienced patients: Clinical and genotypic predictors of virologic response
19. Short-course monotherapy with AG1549, a novel nonnucleoside reverse transcriptase inhibitor (NNRTI), in antiretroviral-naive patients
20. Brief report: Primary infection with zidovudine-resistant human immunodeficiency virus type 1
21. Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an International AIDS Society-USA Panel
22. Reduced antiretroviral drug susceptibility among patients with primary HIV infection
23. Reduced susceptibility to NNRTIs is associated with NNRTI hypersensitivity in virus from HIV-1-infected patients
24. Non-nucleoside reverse transcriptase inhibitor viral hypersensitivity is common and improves short-term virological response
25. HIV-1 isolates that exhibit dose-dependent NNRTI stimulation of reverse transcriptase activity and viral replication
26. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INCAS Trial
27. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection: A randomized, double-blind, placebo-controlled trial
28. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
29. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged antiretroviral therapy
30. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy
31. Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy
32. Selection of antiretroviral resistance in the latent reservoir of human immunodeficiency virus type 1 during successful therapy
33. Evaluation of lymph node virus burden in human immunodeficiency virus-infected patients receiving an efavirenz-based protease inhibitor-sparing highly effective antiretroviral therapy
34. Loss of antiretroviral drug susceptibility at low viral load during early virologic failure in treatment-experienced patients
35. Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group study 359
36. Identification of clinically relevant phenotypic and genotypic breakpoints for ABT-378/r in multiple PI-experienced, NNRTI-naive patients